IntrinsicIntrinsic
← All summaries

AMERICAN PUBLIC EDUCATION INC

APEI
Financials & Chart →

Business Summary

American Public Education, Inc. operates in the postsecondary education market, which the filing describes as large, with more than 4,500 institutions of higher learning, diverse in its business models, and fragmented such that no one institution has a significant market share. The market faces challenges including demand for relevance and return on investment, focus on quality and affordability, changes in consumer demands, a continually changing regulatory environment, fluctuations in enrollment, and rapid technological transformation. The company sits within this landscape as a provider of online and campus-based postsecondary education to approximately 108,600 students through its subsidiary institutions, which include American Public University System, Rasmussen University, and Hondros College of Nursing.

The filing names primary competitors for military students as other institutions offering online instruction and colleges and universities offering on-campus instruction near military installations, as well as the Armed Forces themselves through distance learning programs. For nursing programs, the company competes with a mix of community colleges, public and private postsecondary institutions, and other career-focused nursing colleges. The filing states that APUS is the number one educator of active-duty military and of veterans, and that the company is a national leader in pre-licensure nursing education. The company believes that nursing education provides opportunities to distinguish itself from competitors due to state and regulatory approvals, investment in physical campus facilities, specialized programmatic knowledge, clinical placement requirements, and various standards that nursing schools must meet.

The company generates revenue primarily through instructional services, which includes tuition and technology and laboratory fees, recognized ratably as instructional services are provided over the course or term. Other revenue streams include graduation fees, textbook and other course materials fees, and other fees such as application, enrollment, and transcript fees. The filing describes a shared services model where APEI performs certain business functions on a shared basis for the benefit of APUS, RU, and HCN. The company's revenue is largely driven by the number of students enrolled, the number and types of courses taken, student payor source, and the mix of programs students attend.

The APUS Segment provides online postsecondary education to approximately 88,700 adult learners, with approximately 62% of its students self-reporting that they served in the military on active duty at the time of initial enrollment and approximately 15% self-reporting as a military veteran. APUS offers 133 degree programs and 98 certificate programs across five schools of study, with more than 1,700 distinct courses available in either eight- or sixteen-week formats. The RU Segment provides nursing- and health sciences-focused postsecondary education to approximately 15,900 students at its 18 campuses across five states and online, offering a comprehensive ladder of nursing degrees including a pre-licensure Diploma in PN, ADN, BSN degree, RN to BSN degree, Master of Science in Nursing degree, and Doctorate of Nursing Practice. The HCN Segment provides nursing education to approximately 4,000 students at eight campuses across three states, offering pre-licensure nursing programs including a PN diploma and an ADN, and a Direct Entry ADN option.

The filing details that APUS revenue for the year ended December 31, 2025 was $319.8 million , RU Segment revenue was $246.2 million , and HCN Segment revenue was $75.0 million . APUS net course registrations increased approximately 0.7% to 381,000 for the year ended December 31, 2025, from approximately 378,400 in the 2024 period. RU student enrollment increased 8.7% as compared to the 2024 period, driven by a 9.6% increase in online enrollment and a 7.7% increase in on-ground enrollment. HCN student enrollment increased approximately 12.3% as compared to the 2024 period.

On June 23, 2025, APEI redeemed all 400 outstanding shares of Series A Senior Preferred Stock for $43.1 million , excluding unpaid and accrued dividends of $1.4 million . In the first and second quarters of 2025, APUS completed the sale of an undeveloped parcel of land and two buildings located in Charles Town, West Virginia, for net sales proceeds of approximately $23.0 million . On July 25, 2025, APEI completed the sale of its membership interest in Graduate School USA for $0.5 million . On November 3, 2025, the company completed a reduction in force that resulted in the termination of approximately 40 non-faculty employees at APUS, representing approximately 6.5% of the APUS non-faculty workforce. Separately, in the fourth quarter of 2025, 19 information technology employees at APEI were terminated. On March 2, 2026, the company completed the merger of the legal entities that own and operate APUS, RU, and HCN.

Consolidated revenue in 2025 was $648.9 million , representing a $24.3 million , or 3.9% , increase from $624.6 million in 2024. Net income in 2025 was $31.6 million , compared to $16.1 million in 2024. Net income available to common stockholders in 2025 was $25.3 million , compared to $10.1 million in 2024. Income from operations before interest and income taxes was $47.9 million in 2025, compared to $33.1 million in 2024.

Business Outlook

The filing identifies the planned combination of APUS, RU, and HCN as a key growth vector, which will result in a combined institution named American Public University System comprised of two divisions named APU Global and RU Health+. The company currently expects to complete implementation of step two of the Combination in the third quarter of 2026 , subject to obtaining required approvals. The filing states that with the expected completion of the Combination, there are expected to be revenue synergies and cost synergy opportunities through the elimination of redundancies and optimizing operations. The company expects to incur between approximately $2.0 million and $4.0 million in professional fees in 2026 to complete the Combination.

The filing identifies the expansion of nursing opportunities through geographic campus expansion and the expansion of programs and course offerings as a growth vector. The company intends to continue to seek opportunities for both organic and inorganic growth, including by exploring acquisitions of other nursing schools. The filing also discusses building a career learning platform, noting that APUS partners with community colleges and that together RU and HCN have over 400 corporate alliance partners whose employees can pursue an education at RU or HCN.

The filing discusses that the company aims to increase public market scale by growing revenue organically and inorganically and delivering improved enterprise-wide operating margins. The company expects to continue to develop capabilities to drive organic growth and plans to continue to assess and pursue strategic acquisitions. The filing notes that with the expected completion of the Combination, there are expected to be cost synergy opportunities through the elimination of redundancies and optimizing operations.

The filing discusses a multi-year enterprise technology transformation intended to modernize core platforms, improve student experience, reduce long-term technology risk, and improve operational effectiveness. In 2026, the company plans to begin migrating HCN to a new SIS platform and transition RU from Blackboard Ultra to D2L to consolidate the LMS environment. The company expects to complete certain of these upgrades in 2026 and 2027 . The filing also notes that the company is continuing to transition toward a cloud-based operating model through the phased migration of applications, integration services, and infrastructure workloads to cloud platforms.

The filing states that capital expenditures were $15.9 million in 2025, compared to $21.1 million in 2024. The filing notes that on March 10, 2026, the Board of Directors authorized a common stock repurchase program of up to $50 million in the aggregate, which replaces prior repurchase authorizations. The filing states that as of December 31, 2025, approximately $6.0 million remained available under the November 2023 purchase authorization. The filing does not disclose specific R&D spending levels or a dividend policy.

The filing identifies the 90/10 Rule as a significant headwind, noting that while each institution was in compliance for 2025, APUS's relevant percentage for 2025 was 89% , and there is no assurance the company will continue to be able to comply in future years, particularly at APUS. The filing also discusses the impact of the U.S. federal government shutdown from October 1, 2025 to November 12, 2025, which resulted in suspension of DoD TA programs and an adverse impact on APUS's course registrations, cash flows, results of operations, and financial condition. The filing notes that APUS TA course registrations decreased by approximately 20,600 in the fourth quarter 2025 compared to the prior year period.

The filing identifies the regulatory environment as a constraint, noting that the postsecondary education regulatory environment is complex and continues to evolve, and that changes in or new interpretations of law, regulations, standards, and policies could have material consequences. The filing specifically discusses the One Big Beautiful Bill Act, which was signed into law on July 4, 2025, and makes significant changes to federal student financial aid programs and eligibility requirements, including new caps on federal loans for graduate and professional students and a new accountability framework that could limit the availability of certain programs.

Risk Factors

The most material risk is the 90/10 Rule, as APUS's relevant percentage for 2025 was 89% , and failure to comply for two consecutive years would result in loss of eligibility to participate in Title IV programs and TA, which would have a material adverse effect on enrollments, revenue, results of operations, and cash flows. A second critical risk is the company's dependence on DoD TA programs, as students utilizing TA accounted for 41% of APUS's revenue in 2025, and the 2025 government shutdown resulted in a decrease of approximately 20,600 APUS TA course registrations in the fourth quarter. A third risk is the extensive regulatory environment, including the potential for loss of institutional accreditation, which would render an institution ineligible to participate in Title IV, TA, and VA programs. A fourth risk is the failure to improve NCLEX pass rates, as a number of programs at certain RU campuses and HCN have not met state-established first-time NCLEX benchmarks, which could lead to adverse actions by state boards of nursing, including withdrawal of approval. A fifth risk is the company's financial responsibility composite score, which was 1.3 for fiscal year 2023, placing the institutions in the zone and requiring operation under the zone alternative, though the score improved to 2.6 for fiscal 2024.

Management Priorities

Management's message emphasizes the planned combination of APUS, RU, and HCN as a key strategic initiative, with the filing stating that the company completed the merger of the legal entities on March 2, 2026, and currently expects to complete implementation of step two of the Combination in the third quarter of 2026 , subject to obtaining required approvals. The filing highlights management's focus on the 90/10 Rule, noting that while each institution was in compliance for 2025, APUS's relevant percentage for 2025 was 89% , and compliance will continue to be an area of focus. The filing also discusses management's focus on cost optimization through the shared services model and the expectation of revenue synergies and cost synergy opportunities through the elimination of redundancies and optimizing operations following the Combination. The filing notes that management expects to incur between approximately $2.0 million and $4.0 million in professional fees in 2026 to complete the Combination.

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 7, MD&A — Operating Results by Reportable Segment
  2. [2] Item 7, MD&A — Operating Results by Reportable Segment
  3. [3] Item 7, MD&A — Operating Results by Reportable Segment
  4. [4] Item 7, MD&A — Revenue
  5. [5] Item 7, MD&A — Revenue
  6. [6] Item 7, MD&A — Revenue
  7. [7] Item 7, MD&A — RU Segment
  8. [8] Item 7, MD&A — RU Segment
  9. [9] Item 7, MD&A — Revenue
  10. [10] Item 1, Business — 2025 Developments and Future Financial Objectives
  11. [11] Item 1, Business — 2025 Developments and Future Financial Objectives
  12. [12] Item 1, Business — 2025 Developments and Future Financial Objectives
  13. [13] Item 1, Business — 2025 Developments and Future Financial Objectives
  14. [14] Item 1, Business — 2025 Developments and Future Financial Objectives
  15. [15] Item 1, Business — 2025 Developments and Future Financial Objectives
  16. [16] Item 1, Business — 2025 Developments and Future Financial Objectives
  17. [17] Item 1, Business — 2025 Developments and Future Financial Objectives
  18. [18] Item 7, MD&A — Overview
  19. [19] Item 7, MD&A — Overview
  20. [20] Item 7, MD&A — Overview
  21. [21] Item 7, MD&A — Overview
  22. [22] Item 7, MD&A — Net income
  23. [23] Item 7, MD&A — Net income
  24. [24] Item 7, MD&A — Net income available to common stockholders
  25. [25] Item 7, MD&A — Net income available to common stockholders
  26. [26] Item 7, MD&A — Costs and Expenses
  27. [27] Item 7, MD&A — Costs and Expenses
  28. [28] Item 1, Business — Regulatory Environment — Accreditation — The Planned Combination of APUS, RU, and HCN
  29. [29] Item 7, MD&A — Overview
  30. [30] Item 1, Business — Our Institutions and Operations — Career Development
  31. [31] Item 1, Business — Information Technology
  32. [32] Item 7, MD&A — Investing Activities
  33. [33] Item 7, MD&A — Investing Activities
  34. [34] Item 5, Market for Registrant's Common Equity — Purchases of Equity Securities by the Issuer
  35. [35] Item 5, Market for Registrant's Common Equity — Purchases of Equity Securities by the Issuer
  36. [36] Item 1, Business — 2025 Developments and Future Financial Objectives
  37. [37] Item 7, MD&A — Overview — U.S. Federal Government Shutdown
  38. [38] Item 1, Business — 2025 Developments and Future Financial Objectives
  39. [39] Item 1, Business — Our Institutions and Operations — Sources of Student Financing and Financial Aid
  40. [40] Item 7, MD&A — Overview — U.S. Federal Government Shutdown
  41. [41] Item 1A, Risk Factors — Risks Related to the Regulation of Our Industry
  42. [42] Item 1A, Risk Factors — Risks Related to the Regulation of Our Industry
  43. [43] Item 1, Business — Regulatory Environment — Accreditation — The Planned Combination of APUS, RU, and HCN
  44. [44] Item 1, Business — 2025 Developments and Future Financial Objectives
  45. [45] Item 7, MD&A — Overview
  46. [46] Item 8, Consolidated Statements of Income
  47. [47] Item 8, Consolidated Statements of Income
  48. [48] Item 8, Consolidated Statements of Income
  49. [49] Item 8, Consolidated Statements of Income
  50. [50] Item 8, Consolidated Statements of Income
  51. [51] Item 8, Consolidated Statements of Income
  52. [52] Item 8, Consolidated Statements of Income
  53. [53] Item 8, Consolidated Statements of Income
  54. [54] Item 7, MD&A — Costs and Expenses
  55. [55] Item 7, MD&A — Costs and Expenses
  56. [56] Item 8, Consolidated Statements of Cash Flows
  57. [57] Item 8, Consolidated Statements of Cash Flows
  58. [58] Item 8, Consolidated Balance Sheets
  59. [59] Item 8, Consolidated Balance Sheets
  60. [60] Item 8, Consolidated Balance Sheets
  61. [61] Item 8, Consolidated Balance Sheets
  62. [62] Item 7, MD&A — Costs and Expenses
  63. [63] Item 7, MD&A — Costs and Expenses
  64. [64] Item 7, MD&A — Costs and Expenses
  65. [65] Item 7, MD&A — Costs and Expenses
  66. [66] Item 7, MD&A — Costs and Expenses
  67. [67] Item 7, MD&A — Costs and Expenses
  68. [68] Item 7, MD&A — Costs and Expenses
  69. [69] Item 7, MD&A — Costs and Expenses
  70. [70] Item 7, MD&A — Costs and Expenses
  71. [71] Item 7, MD&A — Costs and Expenses
  72. [72] Item 7, MD&A — Operating Results by Reportable Segment
  73. [73] Item 7, MD&A — Operating Results by Reportable Segment
  74. [74] Item 7, MD&A — Operating Results by Reportable Segment
  75. [75] Item 7, MD&A — Operating Results by Reportable Segment
  76. [76] Item 7, MD&A — Operating Results by Reportable Segment
  77. [77] Item 7, MD&A — Operating Results by Reportable Segment

Analysis on 6/22/2026